✚ HEALTH & MEDICINE 10 YEARS HORIZON RESOLVES 12 NOV 2036 · in 10.0y

The FDA approves a curative therapy that reverses cognitive decline in Alzheimer's patients before 2037.

Pharmaceutical pipelines are testing disease-modifying therapies for Alzheimer's. Resolution requires FDA approval of a treatment certified to reverse or permanently cure existing Alzheimer's disease.

Across 6 frontier models answering independently, the panel has all but ruled it out: the median is 4%.

They broadly agree, 9 points between GPT at 12% and Qwen at 3%.

Nothing is settled until 12 Nov 2036, when the outcome is checked against sources and every number above gets a permanent score.

MODEL BY MODEL

What each one said

  • GPTOpenAI

    It turns on whether a therapy can show durable restoration of lost cognition, not merely slower decline, in pivotal trials.

    • FDA approvals through 2026, including lecanemab and donanemab, slow decline modestly and have not reversed established disease.
    • Sponsors must run multi-year Phase 3 trials showing clinically meaningful, durable cognitive recovery and an acceptable safety profile before 2036.
    • The main upside catalyst would be replicated large cognitive gains from an early tau, neuroregeneration, or combination-therapy trial by 2030.
    openai/gpt-5.6-terra · asked 15 Nov 2026
    12%
  • GrokxAI

    A regenerative or novel-mechanism candidate must show actual cognitive reversal in Phase 3 by ~2033 for 2036 FDA approval.

    • Late-stage AD assets (anti-amyloid/tau) at best slow decline 20-30%; none reverse and none claim that endpoint.
    • Typical AD Phase 3 plus follow-up plus review takes 5–7 years, so only assets already in or entering Phase 2 today could possibly make the window.
    • AD disease-modifying failure rate historically exceeds 99%; regenerative approaches remain preclinical/early-phase with no human reversal precedent.
    x-ai/grok-4.6 · asked 15 Nov 2026
    12%
  • GeminiGoogle

    Neuroregeneration must replace dead cortical circuits, a biological barrier unsupported by any current clinical pipeline.

    • Approved drugs like lecanemab merely slow progression; zero candidates in Phase 2 or 3 demonstrate synaptic reversal or a cure.
    • Developing, validating, and securing FDA labeling for genuine reversal requires over a decade from preclinical proof-of-concept.
    • A phase 2 trial showing statistically significant, sustained cognitive gains via neuronal regrowth would double my probability.
    google/gemini-3.8-flash · asked 15 Nov 2026
    4%
  • ClaudeAnthropic

    Requires a true disease-reversing cure, far beyond current amyloid-clearing drugs that only slow decline.

    • Lecanemab/donanemab only modestly slow decline; no drug in Phase 2/3 pipelines today claims reversal of existing damage.
    • FDA approval needs pivotal trials showing cognitive improvement, which would require a scientific breakthrough not yet in clinical pipelines by 2026.
    • 11-year window allows one full drug development cycle (10-15 years), but curative mechanism must still be discovered, not just advanced.
    anthropic/claude-sonnet-5 · asked 15 Nov 2026
    4%
  • DeepSeekDeepSeek

    Reversing existing Alzheimer's damage requires a mechanism no current pipeline has, and no phase 3 reversal trial is even running.

    • No phase 3 Alzheimer's drug has ever reversed established dementia; lecanemab and donanemab only slow decline ~27-35%.
    • The FDA needs a completed phase 3 with a validated cognitive endpoint, and no such trial reads out before 2030.
    • Anti-amyloid and anti-tau approaches target plaques, not the neuronal loss that already causes symptoms, so reversal is biologically implausible this decade.
    deepseek/deepseek-v4.1-flash · asked 15 Nov 2026
    4%
  • QwenAlibaba

    No therapy has ever reversed neurodegeneration in humans; the bar requires restoring lost neurons or circuits, not just slowing loss.

    • Lecanemab and donanemab slow decline ~30% but don't reverse it; no Phase 3 candidate as of 2026 shows cognitive improvement over baseline.
    • A reversal therapy would need Phase 2 data by ~2029-2030 to clear FDA review by 2036—no such signal exists in any current pipeline.
    • Would move up sharply if a neuroregeneration mechanism (e.g., targeted tau clearance with synaptic regrowth) showed Phase 2 efficacy by 2028.
    qwen/qwen3.8-max-0902 · asked 15 Nov 2026
    3%

6 of 6 models answered · 9 points between the highest and lowest. None was shown the market price.

WHAT DO YOU THINK?
loading…

Question sourced from a news sweep on 15 Nov 2026. Forecast by google/gemini-3.8-flash, anthropic/claude-sonnet-5, openai/gpt-5.6-terra, x-ai/grok-4.6, deepseek/deepseek-v4.1-flash, qwen/qwen3.8-max-0902 via OpenRouter.